Evans Injection (Sodium Ibandronate Dihydrate)

Adult administration

Administer 3 mg intravenously every 3 months over 15 - 30 seconds.

This medication must be administered intravenously, and great caution is required as administering it intra-arterially or around veins may cause tissue damage. Patients who are allergic to this drug or its components, or have untreated hypocalcemia, should not use this medication. During treatment with this drug, gastrointestinal symptoms such as gastritis, diarrhea, abdominal pain, dyspepsia, nausea, constipation, as well as musculoskeletal symptoms such as musculoskeletal pain, arthralgia, and myalgia may occur. Moreover, flu-like symptoms such as fever, chills, fatigue, arthralgia, and myalgia may temporarily occur, most often resolved without interruption of treatment at mild to moderate levels. Among patients receiving this drug, rare reports of skin rash, headaches, and fatigue have been recorded. Rarely, bisphosphonate therapy may lead to osteonecrosis of the jaw, particularly in cancer patients or those receiving dental treatment. It is advisable to undergo oral examination before receiving this drug and to avoid excessive dental procedures during treatment. Osteonecrosis of the external auditory canal has also been reported rarely; consult a physician if there is any ear pain or discharge. During osteoporosis treatment, severe bone, joint, or muscle pain may arise, and it is crucial to inform healthcare providers immediately if such symptoms occur. Patients using this drug for an extended period may experience atypical femoral fractures, so immediate evaluation is essential if pain arises in the thigh or groin. When using this drug, adequate intake of calcium and vitamin D is necessary, and usage should be considered after treatment in cases of hypocalcemia or bone metabolism disorders. This drug is primarily excreted through the kidneys without being metabolized in the liver, so patients with poor kidney function should undergo regular monitoring. Its safety has not been established during pregnancy or breastfeeding; therefore, avoiding its use is recommended. In cases of overdose, renal and liver function should be closely monitored, and appropriate treatment should be administered if hypocalcemia or other electrolyte imbalances occur. This medication should not be mixed with calcium-containing solutions and must only be administered intravenously. After use, the injection needle and syringe should not be reused and should be safely disposed of.

Serious side effects

Urticaria, angioedema, facial swelling/edema, severe allergic reactions (anaphylaxis, shock), Stevens-Johnson syndrome, erythema multiforme, bullous dermatitis, angioedema, respiratory distress, difficulty breathing, severe cutaneous adverse reactions (severe rash, blistering, skin peeling, mucosal pain), headaches (sudden and very severe headaches, thunderclap headaches), paralysis, altered consciousness, visual disturbances, multiple organ failure, death, osteonecrosis, atypical femoral fractures

Mild side effects

Gastritis, diarrhea, abdominal pain, dyspepsia, nausea, constipation, musculoskeletal pain, arthralgia, myalgia, flu-like symptoms (including arthralgia, myalgia, fever, chills, fatigue, nausea, loss of appetite, bone pain), fatigue, headache, rash, back pain, weakness, injection site reactions, phlebitis/thrombophlebitis, sensory impairment, dizziness, insomnia, anxiety, tinnitus, hearing loss, hypothyroidism, lipoma, ocular bleeding, heart failure, urinary disorders,

This medication should be stored in a sealed container to prevent contact with air and kept at room temperature between 1°C and 30°C. Proper storage maintains the drug's efficacy and safety.

Appearance

This injection is a colorless and transparent solution contained in a colorless, transparent glass prefilled syringe, supplied with a single-use needle.

Package unit

3 milliliters/prefilled syringe